Table 2. Evolution of quantitative proteinuria and eGFR by TDF exposure group.
| eGFR a (mL/min/1.73m2/year) | uPCR b (mg/g/month) | |||||
|---|---|---|---|---|---|---|
| Mean slope | 95% confidence interval | P c | Mean slope | 95% confidence interval | P c | |
| TDF discontinuation | -2.04 | -3.69;-0.40 | Ref | -7.7 | -10.0;-5.3 | Ref |
| TDF continuation | -3.77 | -5.14;-2.39 | 0.09 | -3.3 | -5.2;-1.3 | <0.001 |
| No TDF exposure | -2.39 | -4.26;-0.51 | 0.78 | -3.8 | -6.5;-1.2 | 0.004 |
aThe model also includes age, sex, AIDS stage, undetectable viral load and boosted protease inhibitor exposure
bThe model also includes age, sex, AIDS stage, positive hepatitis C serology and boosted protease inhibitor exposure
cP value for comparison of slopes of the groups “TDF continuation” and “no TDF exposure groups” with the group “TDF discontinuation” taken as the reference.